entertainment -WSS

entertainment

author：knowledge 2025-09-29 01:39:07 - browse：4

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Analysis of telehealth claims data suggest service duplication

focus

WSS

3 questions for the future of Biden's cancer moonshot

AI can decode, harness the power of the humane immune system

Colorectal cancer study finds potential in overlooked immune cell

Senate panel eyes new effort on drug shortages

Chan Zuckerberg Biohub Chicago to focus on inflammation

Analysis of telehealth claims data suggest service duplication

focus

entertainment

focus

Psychedelics group wrestles with new pharma identity

Sana to lay off nearly a third of staff, de

Hollywood unions extend contract negotiations for actors

Colorectal cancer study finds potential in overlooked immune cell

After affirmative action ruling, medical educators look to 'holistic review'

3 questions for the future of Biden's cancer moonshot

Virginia high school admissions case could be legal follow

Was Amgen transparent enough on FDA's concern on cancer drug?

Medical leaders decry Supreme Court decision on affirmative action

Why age limits for politicians are a terrible idea

focus

FDA panel signals lack of confidence in Amgen cancer drug data

When women are denied an abortion, their children fare worse than peers

What to expect at HLTH 2023, the health care industry conference

Bristol 'take

Colorectal cancer study finds potential in overlooked immune cell

Analysis of telehealth claims data suggest service duplication

knowledge

entertainment

focus

Wikipedia